Summit Therapeutics: Upcoming Ivonescimab Catalysts Offset by KEYTRUDA Competitive Moat and Execution Risks, Analyst Maintains Neutral Rating Without Price Target
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on Summit Therapeutics (SMMT) on July 24, citing upcoming ivonescimab catalysts offset by Merck's strong KEYTRUDA competitive moat and execution risks. While noting potential clinical relevance from expanded Phase 3 trials, the analyst highlighted challenges in demonstrating superiority over pembrolizumab standards. Consequently, no price target was assigned until competitive positioning clarifies. Barclays also maintained a Hold rating with an $18.00 target.
H.C. Wainwright analyst Mitchell Kapoor has reiterated their neutral stance on SMMT stock, giving a Hold rating on July 24.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Mitchell Kapoor has given his Hold rating due to a combination of factors reflecting both opportunity and uncertainty around ivonescimab and Summit Therapeutics. On one hand, he sees important upcoming catalysts, including the HARMONi-3 data in squamous NSCLC and the 2026 PDUFA decision in EGFR-mutant NSCLC, as well as an expanded Phase 3 footprint that could establish broader clinical relevance.
At the same time, Kapoor highlights that Merck’s sac-TMT strategy meaningfully strengthens the competitive moat around KEYTRUDA, raising the bar for ivonescimab to show clear PFS and OS advantages. He also notes that the new bladder cancer program against the strong pembrolizumab + PADCEV standard is demanding and currently carries no valuation credit, while funding and execution risks rise with more trials. Taken together, these factors justify maintaining a Neutral stance and withholding a formal price target until competitive positioning becomes clearer.
According to TipRanks, Kapoor is a 4-star analyst with an average return of 11.3% and a 42.58% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Incyte, Ionis Pharmaceuticals, and Legend Biotech.
In another report released on July 24, Barclays also maintained a Hold rating on the stock with a $18.00 price target.